Company: Eli Lilly
Job title: Research Fellow
Dr. Sean Buchanan is a Research Fellow leading a preclinical Translational Oncology group at Eli Lilly & Co. based in Indianapolis, Indiana, USA. He earned a BA and PhD at Cambridge University in the UK, and in 1999 joined SGX Pharmaceuticals in San Diego, California as a founding scientist where he led the Oncology Biology department. Dr Buchanan joined Eli Lilly in 2008 and set up a translational research group for oncology in 2010. He has overseen the introduction of pharmacogenomics and synthetic lethal shRNA and CRISPR screening platforms at Eli Lilly and is also the lead preclinical scientist for Lilly’s CDK4/6 inhibitor abemaciclib.
Combination Strategies to Target RAS Mutant Cancers 3:00 pm
RAS mutant cancers have been largely refractory to monotherapy treatment strategies Preclinical studies have shown that RAS mutant cancers are partially vulnerable to inhibitors of (1) the MAPK pathway and (2) CDK4 We have performed CRISPR and drug screens anchored on these inhibitors to identify new combination strategiesRead more
day: Day Two